<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:21bfe35c-88a2-44ed-8c9a-8dd0dea5d01a"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="bad07005-24e7-4b85-b7e8-d43cc40750b5"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-06-07T20:21:23Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:7710a2ab-b43d-4c97-980f-4803f0916438"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#243F60;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#243F60;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:#404040;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-link:"Title Char";
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-link:"Title Char";
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	letter-spacing:.75pt;
	font-style:italic;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin:0in;
	text-indent:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.8in;
	margin-bottom:0in;
	margin-left:.8in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4F81BD;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.5pt;
	font-family:Consolas;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Cambria",serif;
	color:#243F60;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Cambria",serif;
	color:#243F60;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Cambria",serif;
	color:#404040;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;
	font-family:"Times New Roman",serif;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";
	font-family:"Times New Roman",serif;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;
	font-family:"Times New Roman",serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:Consolas;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:Consolas;}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:Consolas;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:normal;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;
	font-family:"Times New Roman",serif;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;
	color:#4F81BD;
	letter-spacing:.75pt;
	font-style:italic;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="B. PACKAGE LEAFLET"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="center" class="MsoNormal" style="text-align:center"></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Package leaflet: Information for the user</span></b></p><p align="center" class="MsoNormal" style="text-align:center;background:white"></p><p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Ovaleap 300 IU/0.5 mL solution for injection</span></b></p><p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Ovaleap 450 IU/0.75 mL solution for injection</span></b></p><p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Ovaleap 900 IU/1.5 mL solution for injection</span></b></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">follitropin alfa</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><b><span lang="EN-GB">Read all of this leaflet carefully before you start using this medicine because it contains important information for you.</span></b></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">-</span><span lang="EN-GB">Keep this leaflet. You may need to read it again. </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">-</span><span lang="EN-GB">If you have any further questions, ask your doctor, pharmacist or nurse.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">-        This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">-</span><span lang="EN-GB">If you get any side effects, talk to your doctor, pharmacist or nurse.</span><span lang="EN-GB">This includes any possible side effects not listed in this leaflet.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="What is in this leaflet"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">1.       What Ovaleap is and what it is used for</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">2.       What you need to know before you use Ovaleap </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">3.       How to use Ovaleap</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">4.       Possible side effects</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">5.       How to store Ovaleap</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">6.       Contents of the pack and other information</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="1.       What Ovaleap is and what it is used for"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="EN-GB">What Ovaleap is</span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">This medicine</span><span lang="EN-GB"> contains </span><span lang="EN-GB">the active substance follitropin alfa, which is almost identical to a natural hormone produced by your body called folliclestimulating hormone (FSH). FSH is a gonadotropin, a type of hormone that plays an important role in human fertility and reproduction. In women, FSH is needed for the growth and development of the sacs (follicles) in the ovaries that contain the egg cells. In men, FSH is needed for the production of sperm.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="EN-GB">What Ovaleap is used for</span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="margin-right:-.1pt"><u><span lang="EN-GB">In adult women, Ovaleap is used:</span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        to help ovulation (release of a mature egg cell from the follicle) in women that cannot ovulate and that have not responded to treatment with a medicine called clomifene citrate.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        to help follicles develop in women undergoing assisted reproductive technology procedures (procedures that may help you to become pregnant) such as <i>in vitro </i>fertilisation, gamete intrafallopian transfer or zygote intrafallopian transfer.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        in combination with a medicine called lutropin alfa (a version of another gonadotropin, luteinising hormone or LH) to help ovulation in women that are not ovulating because their body is producing too little FSH and LH.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">In adult men, Ovaleap is used:</span></u></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        in combination with a medicine called human chorionic gonadotropin (hCG) to help produce sperm in men that are infertile due to low levels of certain hormones.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       What you need to know before you use Ovaleap"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Do not use Ovaleap:"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        if you are allergic to follitropin alfa, Follicle Stimulating Hormone (FSH) or any of the other ingredients of </span><span lang="EN-GB">this medicine (listed in section 6)</span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        if you have a tumour in your hypothalamus or pituitary gland (parts of the brain).</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        if you are a <b><i>woman </i></b>with:</span></p><p class="MsoNormal" style="margin-left:56.7pt"><span lang="EN-GB">- large ovaries or sacs of fluids within the ovaries (ovarian cysts) of unknown origin.</span></p><p class="MsoNormal" style="margin-left:56.7pt"><span lang="EN-GB">- unexplained vaginal bleeding.</span></p><p class="MsoNormal" style="margin-left:56.7pt"><span lang="EN-GB">- cancer in your ovaries, womb or breasts.</span></p><p class="MsoNormal" style="margin-left:56.7pt"><span lang="EN-GB">- any condition that usually makes normal pregnancy impossible, such as ovarian failure (early menopause), fibroid tumours of the womb or malformed reproductive organs.</span></p><p class="MsoNormal"><span lang="EN-GB">        if you are a <b><i>man</i></b> with:</span></p><p class="MsoNormal" style="margin-left:56.7pt"><span lang="EN-GB">- testicular failure that is not treatable.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Do not use </span><span lang="EN-GB">this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before using this medicine.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Warnings and precautions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Before the treatment is started you and your partners fertility should be evaluated by a doctor experienced in treating fertility disorders.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">Porphyria</span></u></p><p class="MsoNormal"><span lang="EN-GB">Tell your doctor before you start treatment, if you or any member of your family have porphyria. This is a condition that may be passed on from parents to children which means that you have an inability to break down porphyrins (organic compounds).</span></p><p class="MsoNormal"><span lang="EN-GB">Tell your doctor straight away if:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        your skin becomes fragile and easily blistered, especially skin that has been frequently in the sun, and/or</span></p><p class="MsoNormal"><span lang="EN-GB">        you have stomach, arm or leg pain.</span></p><p class="MsoNormal"><span lang="EN-GB">If you experience the above symptoms your doctor may recommend that you stop treatment.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">Ovarian HyperStimulation Syndrome (OHSS)</span></u></p><p class="MsoNormal"><span lang="EN-GB">If you are a woman, this medicine increases your risk of developing OHSS. This is when your follicles develop too much and become large cysts.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Talk to your doctor straight away if:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        you get pain in the lower part of the abdomen (belly),</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        you gain any weight rapidly,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        you feel sick or are vomiting,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        you have difficulty in breathing.</span></p><p class="MsoNormal"><span lang="EN-GB">If you experience the above symptoms your doctor might ask you to stop using this medicine (see also section 4</span><span lang="EN-GB"> under </span><span lang="EN-GB">Serious side effects in women").</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">If you are not ovulating and if the recommended dose and timing are followed, the occurrence of OHSS is less likely. Ovaleap treatment seldom causes severe OHSS unless the medicine that is used for final follicular maturation (containing human chorionic gonadotropin, hCG) is given. If you are developing OHSS your doctor may not give you any hCG in this treatment cycle. You may be told not to have sex or to use a barrier contraceptive method for at least 4 days.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">Multiple pregnancy</span></u></p><p class="MsoNormal"><span lang="EN-GB">When using </span><span lang="EN-GB">this medicine</span><span lang="EN-GB">, you have a higher risk of being pregnant with more than one child (i.e. multiple pregnancy, typically twins) than if you conceived naturally. Multiple pregnancy may lead to medical complications for you and your babies. You can reduce the risk of multiple pregnancy by using the right dose of </span><span lang="EN-GB">this medicine</span><span lang="EN-GB"> at the right times. When undergoing assisted reproductive technology the risk of having a multiple pregnancy is related to your age, the quality and number of fertilised eggs or embryos placed inside you.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">Miscarriage</span></u></p><p class="MsoNormal"><span lang="EN-GB">You are more likely to have a miscarriage than the average woman when undergoing assisted reproductive technology or stimulation of your ovaries to produce eggs.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">Ectopic pregnancy</span></u></p><p class="MsoNormal"><span lang="EN-GB">You are more likely to have a pregnancy outside the womb (an ectopic pregnancy) than the average woman when undergoing assisted reproductive technology and if you have damaged fallopian tubes.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:black">Birth defects</span></u></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">When being conceived by assisted reproductive technology, a baby may have a slightly higher risk of birth defects  than after natural conception. This could be related to multiple pregnancies or to parent characteristics such as maternal age and sperm characteristics.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">Blood clotting problems (thromboembolic events)</span></u></p><p class="MsoNormal"><span lang="EN-GB">If you have ever had blood clots in your leg or lung, or a heart attack or stroke, or if your family have experienced these, inform your doctor. You might have a higher risk of these problems occurring or becoming worse with Ovaleap treatment.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">Men with too much FSH in their blood</span></u></p><p class="MsoNormal"><span lang="EN-GB">If you are a man, having too much natural FSH in your blood can be a sign of damaged testicles. </span><span lang="EN-GB">This medicine</span><span lang="EN-GB"> usually does not work if you have this problem. If your doctor decides to try Ovaleap treatment, they may monitor it by asking you to provide semen for analysis 4 to 6 months after starting treatment.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Children and adolescents"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><span lang="EN-GB">T</span><span lang="EN-GB">his medicine</span><span lang="EN-GB"> is not indicated for use in children and adolescents </span><span lang="EN-GB">less than 18 years of age.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Other medicines and Ovaleap"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Tell your doctor or pharmacist if you are </span><span lang="EN-GB">using</span><span lang="EN-GB">, have recently used </span><span lang="EN-GB">or might use </span><span lang="EN-GB">any other medicines.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        If you use Ovaleap with other medicines which help ovulation such as human chorionic gonadotropin (hCG) or clomifene citrate, this may increase the response of your follicles.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        If you use Ovaleap at the same time as a gonadotropin-releasing hormone (GnRH) agonist or antagonist (these medicines reduce your sex hormone levels and stop you ovulating) you may need a higher dose of Ovaleap to produce follicles.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Pregnancy and breastfeeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><span lang="EN-GB">You should not use </span><span lang="EN-GB">this medicine</span><span lang="EN-GB"> if you are pregnant or breastfeeding.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Driving and using machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">This medicine does not affect your ability to drive and use machines.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Ovaleap contains sodium, benzalkonium chloride and benzyl alcohol"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><span lang="EN-GB">This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">This medicine also contains 0.02 mg per mL of benzalkonium chloride and </span><span lang="EN-GB">10.0 mg per mL of benzyl alcohol. Ask your doctor or pharmacist for advice if you have a liver or kidney disease, and if you are pregnant or breast-feeding. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called metabolic acidosis).</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       How to use Ovaleap"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Always use </span><span lang="EN-GB">this medicine</span><span lang="EN-GB"> exactly as your doctor </span><span lang="EN-GB">or pharmacist </span><span lang="EN-GB">has told you. Check with your doctor or pharmacist if you are not sure.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">This medicine is given as an injection into the tissue just under the skin (subcutaneous injection). </span><span lang="EN-GB">Your doctor or nurse will show you how to inject the medicine. If you administer this medicine to yourself, please carefully read and follow the Instructions for Use of the pen.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="EN-GB">What the </span><span lang="EN-GB">recommended</span></b><b><span lang="EN-GB"> dose is</span></b></p><p class="MsoNormal"><span lang="EN-GB">Your doctor will decide how much medicine you will take and how often. The doses described below are stated in International Units (IU).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">Women</span></u></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">If you are not ovulating and have irregular or no periods</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">        This medicine is usually given every day.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        If you have irregular periods, start using this medicine within the first 7 days of your menstrual cycle. If you do not have periods, you can start using the medicine on any convenient day.</span></p><p class="MsoNormal"><span lang="EN-GB">        The usual starting dose of this medicine is 75 to 150 IU each day.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        Your dose of this medicine may be increased every 7 or every 14 days by 37.5 to 75 IU, until you get the desired response.</span></p><p class="MsoNormal"><span lang="EN-GB">        The maximum daily dose of this medicine is usually not higher than 225 IU.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        When you get the desired response, you will be given hCG or recombinant hCG (rhCG, an hCG made in a laboratory by a special DNA technique). The single injection will be 250 micrograms of rhCG or 5,000 to 10,000 IU of hCG, 24 to 48 hours after your last Ovaleap injection. The best time to have sex is on the day of the hCG injection and the day after. Alternatively, intrauterine insemination may be performed by placing the sperm into the womb cavity.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">If your doctor cannot see a desired response after 4 weeks, that treatment cycle with Ovaleap should be stopped. For the following treatment cycle, your doctor will give you a higher starting dose of this medicine than before.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">If your body responds too strongly, your treatment will be stopped and you will not be given any hCG [</span><span lang="EN-GB">see also section 2 under Ovarian HyperStimulation Syndrome (OHSS)</span><span lang="EN-GB">]. For the following cycle, your doctor will give you a lower dose of Ovaleap than before.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">If you need to develop several eggs for collection prior to any assisted reproductive technology</span></u></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        The usual starting dose of this medicine is 150 to 225 IU each day, from day 2 or 3 of your menstrual cycle.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        The dose may be increased, depending on your response. The maximum daily dose is 450 IU.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        Treatment is continued until your eggs have developed to a desired point. This usually takes about 10 days but can take any time between 5 and 20 days. Your doctor will use blood tests and/or an ultrasound machine to check when this is.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        When your eggs are ready, you will be given hCG or rhCG. The single injection will be 250 micrograms of rhCG or 5,000 to 10,000 IU of hCG, 24 to 48 hours after the last Ovaleap injection. This gets your eggs ready for collection.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"></p><p class="MsoNormal"><span lang="EN-GB">In other cases, your doctor may first stop you from ovulating by using a gonadotropinreleasing hormone (GnRH) agonist or antagonist. Then Ovaleap is given approximately 2 weeks after the start of agonist treatment. The Ovaleap and GnRH agonist are then both given until your follicles develop as desired.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">If you are not ovulating, have no periods and have been diagnosed with very low levels of FSH and LH hormones</span></u></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        The usual starting dose of Ovaleap is 75 to 150 IU together with 75 IU of lutropin alfa.</span></p><p class="MsoNormal"><span lang="EN-GB">        You will use these two medicines each day for up to 5 weeks.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        Your dose of Ovaleap may be increased every 7 or every 14 days by 37.5 to 75 IU, until you get the desired response.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        When you get the desired response, you will be given hCG or rhCG. The single injection will be 250 micrograms of rhCG or 5,000 to 10,000 IU of hCG, 24 to 48 hours after your last injections of Ovaleap and lutropin alfa. The best time to have sex is on the day of the hCG injection and the day after. Alternatively, intrauterine insemination may be performed by placing the sperm into the womb cavity.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"></p><p class="MsoNormal"><span lang="EN-GB">If your doctor cannot see a response after 5 weeks, that treatment cycle should be stopped. For the following cycle, your doctor will give you a higher starting dose of this medicine than before.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">If your body responds too strongly, your treatment with Ovaleap will be stopped and you will not be given any hCG [</span><span lang="EN-GB">see also section 2 under Ovarian HyperStimulation Syndrome (OHSS)</span><span lang="EN-GB">]. For the following cycle, your doctor will give you a lower dose of Ovaleap than before.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Men</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">        The usual dose of this medicine is 150 IU together with hCG.</span></p><p class="MsoNormal"><span lang="EN-GB">        You will use these two medicines three times a week for at least 4 months.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">        If you have not responded to treatment after 4 months, your doctor may suggest that you continue using these two medicines for at least 18 months.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal"><b><span lang="EN-GB">How are the injections given?</span></b></p><p class="MsoNormal"><span lang="EN-GB">This medicine is given as an injection into the tissue just under the skin (subcutaneous injection) using the Ovaleap Pen. The Ovaleap Pen is a device (a pen) used for giving injections into the tissue just under the skin.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Your doctor may suggest that you learn how to inject yourself with this medicine. Your doctor or nurse will give you instructions on how to do this and </span><span lang="EN-GB" style="color:black">you can also find instructions</span><span lang="EN-GB"> in the separate instructions for use of the pen</span><span lang="EN-GB">. Do not attempt to selfadminister this medicine without this training by your doctor or nurse. The very first injection of </span><span lang="EN-GB">this medicine </span><span lang="EN-GB">should only be given in the presence of a doctor or nurse.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Ovaleap solution for injection in cartridges has been developed for use in the Ovaleap Pen. You must follow the separate instructions for use of the Ovaleap Pen carefully. The instructions for use of the pen will be provided together with the Ovaleap Pen.</span><span lang="EN-GB"> Proper treatment of your condition, however, requires close and constant cooperation with your doctor.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Discard used needles immediately after injection.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="If you use more Ovaleap than you should"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">The effects of using too much Ovaleap are unknown. Nevertheless one could expect Ovarian HyperStimulation Syndrome (OHSS) to occur, which is described in section 4 under Serious side effects in women". However, the OHSS will only occur if hCG is also administered [see also section 2 under Ovarian HyperStimulation Syndrome (OHSS)].</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="If you forget to use Ovaleap"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Do not use a double dose to make up for a forgotten dose. Please talk to your doctor as soon as you realise that you forgot a dose.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="EN-GB">If you have any further questions on the use of this medicine, ask your doctor, pharmacist </span><span lang="EN-GB">or nurse.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       Possible side effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="EN-GB">Like all medicines, this medicine can cause side effects, although not everybody gets them.</span></p><p class="MsoNormal" style="margin-right:-1.45pt"></p><p class="MsoNormal" style="margin-right:-1.45pt"><b><span lang="EN-GB">Important side effects</span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"></p><p class="MsoNormal" style="margin-right:-1.45pt"><u><span lang="EN-GB">Serious side effects in men and women</span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Allergic reactions such as skin rash, raised itchy areas of skin and severe allergic reactions with weakness, drop in blood pressure, difficulty breathing and swelling of the face have been reported very rarely (may affect up to 1 in 10,000 people). If you think you are having this type of reaction, you must stop your Ovaleap injection and get medical help immediately.</span></p><p class="MsoNormal" style="margin-right:-1.45pt"></p><p class="MsoNormal" style="margin-right:-1.45pt"><u><span lang="EN-GB">Serious side effects in women</span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Lower stomach ache together with nausea or vomiting may be the symptoms of Ovarian HyperStimulation Syndrome (OHSS). This may indicate that the ovaries overreacted to the treatment and that large ovarian cysts developed [see also section 2 under Ovarian HyperStimulation Syndrome (OHSS)]. This side effect is common (may affect up to 1 in 10 people).</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and/or possible fluid accumulation in your stomach or chest. This side effect is uncommon (may affect up to 1 in 100 people).</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Complications of OHSS such as twisting of ovaries or blood clotting may occur rarely (may affect up to 1 in 1,000 people).</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.45pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Serious blood clotting complications (thromboembolic events), sometimes independent of OHSS, may be found very rarely (may affect up to 1 in 10,000 people). This could cause chest pain, breathlessness, stroke or heart attack [see also section 2 under Blood clotting problems (thromboembolic events)].</span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="EN-GB">If you notice any of the above-listed side effects you should immediately contact your doctor who may ask you to stop using Ovaleap.</span></p><p class="MsoNormal" style="margin-right:-1.45pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="EN-GB">Other side effects in women</span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><u><span lang="EN-GB">Very common</span></u><span lang="EN-GB"> (</span><span lang="EN-GB">may affect more than 1 in 10 people)</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Local reactions at the injection site, such as pain, redness, bruising, swelling and/or irritation</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Headache</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Sacs of fluid within the ovaries (ovarian cysts)</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><u><span lang="EN-GB">Common</span></u><span lang="EN-GB"> (</span><span lang="EN-GB">may affect up to 1 in 10 people)</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Stomach ache</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Abdominal bloating</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Abdominal cramps</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Feeling sick</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Vomiting</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Diarrhoea</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><u><span lang="EN-GB">Very rare</span></u><span lang="EN-GB"> (</span><span lang="EN-GB">may affect up to 1 in 10,000 people)</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Your asthma may get worse.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><b><span lang="EN-GB">Other side effects in men</span></b></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><u><span lang="EN-GB">Very common</span></u><span lang="EN-GB"> (</span><span lang="EN-GB">may affect more than 1 in 10 people)</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Local reactions at the injection site, such as pain, redness, bruising, swelling and/or irritation</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><u><span lang="EN-GB">Common</span></u><span lang="EN-GB"> (</span><span lang="EN-GB">may affect up to 1 in 10 people)</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Swelling of the veins above and behind the testicles (a varicocele)</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><a name="OLE_LINK4"></a><a name="OLE_LINK5"><span lang="EN-GB">        </span></a><span lang="EN-GB">Breast development</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Acne</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Weight gain</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><u><span lang="EN-GB">Very rare</span></u><span lang="EN-GB"> (</span><span lang="EN-GB">may affect up to 1 in 10,000 people)</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="EN-GB">        Your asthma may get worse.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Reporting of side effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><span lang="EN-GB">If you get any side effects, </span><span lang="EN-GB">talk to your doctor, pharmacist or nurse.</span><span lang="EN-GB"> This includes any possible side effects not listed in this leaflet. You can also report side effects directly via <span style="background:lightgrey">the national reporting system listed in </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="background:lightgrey">Appendix V</span></a></span><span lang="EN-GB">.</span><span lang="EN-GB">. By reporting side effects you can help provide more information on the safety of this medicine.</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       How to store Ovaleap"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Keep </span><span lang="EN-GB">this medicine </span><span lang="EN-GB">out of the sight and reach of children.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Do not use this medicine after the expiry date which is stated on the label and outer carton after EXP. The expiry date refers to the last day of that month.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Store in a refrigerator (2 C  8 C).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Do not freeze.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Keep the cartridge in the outer carton in order to protect from light.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Before opening and within its shelf life, you may remove this medicine from the refrigerator, without being refrigerated again, for up to 3 months. Do not store above 25 C. You must discard this medicine if it has not been used after 3 months.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Once opened, the cartridge inuse in the pen may be stored for a maximum of 28 days. Do not store above 25 C. Write down the date of first use in the patient diary, which will be provided with the Ovaleap Pen.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Put the pen cap back on the <span style="color:black">Ovaleap Pen</span> after each injection <span style="color:black">in order to protect the cartridge from light.</span></span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Do not use this medicine if you notice i</span><span lang="EN-GB">t is cloudy or there are particles in it.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Do not </span><span lang="EN-GB">throw away any medicines </span><span lang="EN-GB">via wastewater. Ask your pharmacist how to </span><span lang="EN-GB">throw away </span><span lang="EN-GB">medicines you no longer use. These measures will help protect the environment.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       Contents of the pack and other information"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="What Ovaleap contains "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">-</span><span lang="EN-GB">The active substance is follitropin alfa.<br/> Ovaleap 300 IU/0.5 mL: Each cartridge contains 300 IU <span style="color:black">(equivalent to 22 micrograms) </span>follitropin alfa in 0.5 mL solution.<br/> Ovaleap 450 IU/0.75 mL: Each cartridge contains 450 IU <span style="color:black">(equivalent to 33 micrograms) </span>follitropin alfa in 0.75 mL solution.<br/> Ovaleap 900 IU/1.5 mL: Each cartridge contains 900 IU <span style="color:black">(equivalent to 66 micrograms) </span>follitropin alfa in 1.5 mL solution.<br/> <span style="color:black">Each mL of the solution contains 600 IU (equivalent to 44 micrograms) follitropin alfa.</span></span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">-</span><span lang="EN-GB">The other ingredients</span><span lang="EN-GB">are sodium dihydrogen phosphate dihydrate, sodium hydroxide (2 M) (for pH adjustment), mannitol, methionine, polysorbate 20, benzyl alcohol, benzalkonium chloride and water for injections.</span></p><p class="MsoNormal" style="margin-left:28.35pt"><span lang="EN-GB">All strengths listed above contain the other ingredients.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="What Ovaleap looks like and contents of the pack"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><span lang="EN-GB">Ovaleap</span><span lang="EN-GB"> is a solution for injection (injection). Ovaleap is a clear and colourless solution.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Ovaleap 300 IU/0.5 mL is available in packs containing 1 cartridge and 10 injection needles.<br/> Ovaleap 450 IU/0.75 mL is available in packs containing 1 cartridge and 10 injection needles.<br/> Ovaleap 900 IU/1.5 mL is available in packs containing 1 cartridge and 20 injection needles.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="EN-GB">Marketing Authorisation Holder</span></b></p><p class="MsoNormal"><span lang="NL">Theramex Ireland Limited</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">3<sup>rd</sup> Floor, </span><span lang="NL">Kilmore House,</span></p><p class="MsoNormal"><span lang="NL">Park Lane, Spencer Dock,</span></p><p class="MsoNormal"><span lang="NL">Dublin 1</span></p><p class="MsoNormal"><span lang="NL">D01 YE64</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="NL">Ireland</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="EN-GB">Manufacturer</span></b></p><p class="MsoNormal"><a name="OLE_LINK8"></a><a name="OLE_LINK9"><span lang="EN-GB">Teva Biotech GmbH</span></a></p><p class="MsoNormal"><span lang="EN-GB">Dornierstrae 10</span></p><p class="MsoNormal"><span lang="EN-GB">89079 Ulm</span></p><p class="MsoNormal"><span lang="EN-GB">Germany</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="background:silver"><span lang="EN-GB" style="color: black">Teva Pharmaceuticals Europe B.V.</span></p><p class="MsoNormal" style="background:silver"><span lang="EN-GB" style="color: black">Swensweg 5</span></p><p class="MsoNormal" style="background:silver"><span lang="EN-GB" style="color: black">2031 GA Haarlem</span></p><p class="MsoNormal" style="background:silver"><span lang="EN-GB" style="color: black">The Netherlands</span></p><p class="MsoNormal" style="margin-right:-28.4pt"></p><p class="MsoNormal" style="background:silver"><span lang="EN-GB" style="color: black">Merckle GmbH</span></p><p class="MsoNormal" style="background:silver"><span lang="EN-GB" style="color: black">Graf-Arco-Strae 3</span></p><p class="MsoNormal" style="background:silver"><span lang="EN-GB" style="color: black">89079 Ulm, </span></p><p class="MsoNormal" style="background:silver"><span lang="EN-GB" style="color: black">Germany</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="This leaflet was last revised in {month YYYY}."/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Detailed information on this medicine is available on the European Medicines Agency web site: </span><span lang="EN-GB"><a href="http://www.ema.europa.eu"><span style="color:windowtext;text-decoration:none">http://www.ema.europa.eu</span></a></span><span lang="EN-GB">.</span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>